Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

997124

registered interest
date	29/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Housing: Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to promote public awareness of the the effect on people's health of poor quality indoor environments.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	184965
answer	answer is ministerial correction date of answer 06/11/2018 answer text <p>Public Health England (PHE) raises public awareness of the impacts of indoor air pollution by supporting activities that aim to change behaviour, such as the annual Clean Air Day, and is working with health partners, such as the National Institute for Health and Care Excellence, World Health Organization and Allergy UK, to improve the evidence on the health impacts of poor indoor air quality which will enhance advice to the public. PHE also promotes awareness about carbon monoxide through the use of blog posts, press releases and social media updates.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/11/2018 16:28:25 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1008457

registered interest
date	16/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Statins
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the supply of statins after the UK leaves the EU.
tabling member constituency	Tooting
tabling member printed	Dr Rosena Allin-Khan
uin	192116
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>Until we can be certain of the outcome of Brexit negotiations our duty as a responsible government is to prepare for all eventualities, including ‘no deal’. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand that statins are vitally important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:21:08 answering member 4067 label Biography information for Steve Brine
tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1008479

registered interest
date	16/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to make flash glucose monitoring technology available to all patients with diabetes across clinical commissioning groups.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	192108
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>Following an announcement by NHS England on 14 November 2018, flash glucose monitoring systems will be made available on prescription for all patients with type 1 diabetes who meet National Health Service criteria from April 2019.</p><p> </p><p>No estimate has been made of the potential savings related to making flash glucose monitoring technology available to all patients with diabetes.</p><p> </p><p>A search of the Department’s Ministerial correspondence database has identified 272 items of correspondence from members of the public received in 2018 about flash glucose monitoring. This figure represents correspondence received by the Department’s Ministerial correspondence unit only. The Department has not been able to identify any correspondence specifically from charities.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 192109 192110 question first answered 26/11/2018 17:43:55 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

1008480

registered interest
date	16/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the potential savings to the NHS of making flash glucose monitoring technology available to all patients with diabetes across NHS clinical commissioning groups.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	192109
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>Following an announcement by NHS England on 14 November 2018, flash glucose monitoring systems will be made available on prescription for all patients with type 1 diabetes who meet National Health Service criteria from April 2019.</p><p> </p><p>No estimate has been made of the potential savings related to making flash glucose monitoring technology available to all patients with diabetes.</p><p> </p><p>A search of the Department’s Ministerial correspondence database has identified 272 items of correspondence from members of the public received in 2018 about flash glucose monitoring. This figure represents correspondence received by the Department’s Ministerial correspondence unit only. The Department has not been able to identify any correspondence specifically from charities.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 192108 192110 question first answered 26/11/2018 17:43:55 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

1007757

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Levetiracetam
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of the UK leaving the EU on the availability of Keppra for people with epilepsy.
tabling member constituency	Crewe and Nantwich
tabling member printed	Laura Smith
uin	191984
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The United Kingdom’s position on medicines regulation remains clear. We want to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally. As the Prime Minister has said, we intend to to explore with the EU the terms on which the UK could remain part the European Medicines Agency.</p><p> </p><p>Until we can be certain of the outcome of Brexit negotiations our duty as a responsible Government is to prepare for all eventualities, including ‘no deal’. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand that the medicine Keppra is important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 11:54:10 answering member 4067 label Biography information for Steve Brine
tabling member	4648 label Biography information for Laura Smith

1007767

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	191928
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).</p><p> </p><p>NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.</p><p> </p><p>NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE’s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:13:09 answering member 4067 label Biography information for Steve Brine
tabling member	4249 label Biography information for Anne Marie Morris

1007772

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191929
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191930 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007773

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191930
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007775

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191931
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007776

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191932
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191931 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion